Furthermore, patients treated with DPP-4 inhibitor/metformin combination therapy had a lower risk of autoimmune disease, including IBD, compared to those receiving non-DPP-4 inhibitor/metformin regimens [104]. This evidence concerns the gene DPP4 and irritable bowel syndrome.